menu search

SNY / Sanofi's blockbuster Dupixent drug clears major trial

Sanofi's blockbuster Dupixent drug clears major trial
French pharma multinational Sanofi's Dupixent drug has achieved impressive results in a late-stage trial to treat chronic obstructive pulmonary disease (COPD), aka ‘smoker's lung'. Developed jointly with US biotech group Regeneron, Dupixent caused a 30% reduction in moderate or severe acute exacerbations of COPD among a trial group of 939 current or former smokers. Read More
Posted: Mar 23 2023, 10:43
Author Name: Proactive Investors
Views: 112331

SNY News  

This Stock Just Dropped By 15%: Is It a Buy?

By The Motley Fool
November 3, 2023

This Stock Just Dropped By 15%: Is It a Buy?

Sanofi's third-quarter results weren't great, and the company announced a business separation. The biotech will lower its operating income margin targ more_horizontal

Sanofi stock recovers slightly after last week's plunge

By Yahoo Finance
October 30, 2023

Sanofi stock recovers slightly after last week's plunge

Sanofi (SNY) shares are trending higher after plummeting last Friday, after the pharmaceutical company missed third-quarter earnings expectations, los more_horizontal

Sanofi (SNY) Q3 2023 Earnings Call Transcript

By Seeking Alpha
October 27, 2023

Sanofi (SNY) Q3 2023 Earnings Call Transcript

Sanofi (NASDAQ:SNY ) Q3 2023 Earnings Conference Call October 27, 2023 9:00 AM ET Company Participants Eva Schaefer-Jansen - Head of Investor Relation more_horizontal

Sanofi (SNY) Beats on Q3 Earnings, to Spin-Off Consumer Unit

By Zacks Investment Research
October 27, 2023

Sanofi (SNY) Beats on Q3 Earnings, to Spin-Off Consumer Unit

Sanofi (SNY) beats third-quarter estimates for earnings but misses the same for sales. It announces plans to separate its Consumer unit into a new pub more_horizontal

SNY Stock Sinks 15% as Sanofi Plans Consumer Unit Spinoff

By InvestorPlace
October 27, 2023

SNY Stock Sinks 15% as Sanofi Plans Consumer Unit Spinoff

Sanofi (NYSE: SNY ) stock fell about 15% overnight after it predicted slower profit growth next year. The French drug company also said it will follow more_horizontal

Sanofi CEO Paul Hudson on Q3 results: Increased R&D spending will impact 2024 profit

By CNBC Television
October 27, 2023

Sanofi CEO Paul Hudson on Q3 results: Increased R&D spending will impact 2024 profit

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, spin off of its consumer health care business, growth o more_horizontal

Sanofi shares skid as French drugmaker outlines higher R&D expenses, taxes

By Market Watch
October 27, 2023

Sanofi shares skid as French drugmaker outlines higher R&D expenses, taxes

Shares of French drugmaker Sanofi fell as much as 16% on Friday after after hiking its research-and-development expense guidance as well as its expect more_horizontal

Sanofi takes page from rivals' separation playbook

By Reuters
October 27, 2023

Sanofi takes page from rivals' separation playbook

Sanofi on Friday mapped out a potential separate listing of its consumer healthcare business from the fourth quarter of next year, as it plans to shor more_horizontal


Search within

Pages Search Results: